- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 17-09-2025: Press Release
17-09-2025 | 04:14 pm
17-09-2025 | 04:14 pm
Biocon Biologics received U.S. FDA approval for Bosaya™ (Prolia biosimilar) and Aukelso™ (Xgeva biosimilar). This enhances their oncology and osteoporosis portfolios, tapping into a U.S. market with nearly $5 billion in annual sales. Major growth catalyst.
No comments yet. Be the first to comment!